EFFICACY OF OLANZAPINE CONTAINING REGIMEN IN PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN PATIENTS OF BREAST CANCER RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY

Objective: To investigate the efficacy of Olanzapine containing regimen as prophylaxis of Chemotherapy Induced Nausea/Vomiting (CINV) in patients with breast cancer, receiving Highly Ematogenic Chemotherapy (HEC). Study Design: Quasi experimental study. Place and Duration of Study: This study...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Muhammad Umair, Iftikhar Hussain, Nadeem Piracha, Mansoor Zeeshan
Formato:	article
Lenguaje:	EN
Publicado:	Army Medical College Rawalpindi 2019
Materias:	chemotherapy induced nausea/vomiting highly ematogenic chemotherapy Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/e0a3d79970564976972276abc7fefc83
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e0a3d79970564976972276abc7fefc83
record_format	dspace
spelling	oai:doaj.org-article:e0a3d79970564976972276abc7fefc832021-11-11T02:54:39ZEFFICACY OF OLANZAPINE CONTAINING REGIMEN IN PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN PATIENTS OF BREAST CANCER RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY0030-96482411-8842https://doaj.org/article/e0a3d79970564976972276abc7fefc832019-10-01T00:00:00Zhttps://www.pafmj.org/index.php/PAFMJ/article/view/3437/2409https://doaj.org/toc/0030-9648https://doaj.org/toc/2411-8842Objective: To investigate the efficacy of Olanzapine containing regimen as prophylaxis of Chemotherapy Induced Nausea/Vomiting (CINV) in patients with breast cancer, receiving Highly Ematogenic Chemotherapy (HEC). Study Design: Quasi experimental study. Place and Duration of Study: This study was carried out at department of Medical Oncology, CMH Rawalpindi, from Aug 2015 till Feb 2017. Methodology: After meeting the inclusion/exclusion criteria, 44 patient of breast cancer receiving Doxorubicin and Cyclophosphamide chemotherapy, were equally divided in group A and B. Group A received conventional ondansetron IV (8mg), dexamethasone IV (8mg) and Zantac IV (50mg) on day 0 (30 min before chemotherapy) with ondansetron PO (8mg) BD on day 1 and 2, while group B received olanzapine PO (10mg), dexamethasone IV (8mg) and ondansetron IV (8mg) on day 0 with olanzapine PO (10mg) OD on day 1 and 2. Nausea / vomiting scores were calculated in each patient from Day 0 till Day 6. Any episode of rescue medication was also recorded for control of breakthrough nausea/vomiting. The primary efficacy point was to compare complete response between 2 groups, where complete response was defined as Nausea score <2, Vomiting score 0 and no use of rescue medications. Results: Twenty out of 22 patients (90.9%) showed a complete response in group B, whereas only 8 (36.4%) out of 22 (36.4%) patients showed complete response in group A. Conclusion: Olanzapine containing regimen has shown better efficacy than conventional CINV prophylaxis regimen for patients receiving HEC in breast cancer.Muhammad UmairIftikhar HussainNadeem PirachaMansoor ZeeshanArmy Medical College Rawalpindiarticlechemotherapy induced nausea/vomitinghighly ematogenic chemotherapyMedicineRMedicine (General)R5-920ENPakistan Armed Forces Medical Journal, Vol 69, Iss 5, Pp 1139-1143 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	chemotherapy induced nausea/vomiting highly ematogenic chemotherapy Medicine R Medicine (General) R5-920
spellingShingle	chemotherapy induced nausea/vomiting highly ematogenic chemotherapy Medicine R Medicine (General) R5-920 Muhammad Umair Iftikhar Hussain Nadeem Piracha Mansoor Zeeshan EFFICACY OF OLANZAPINE CONTAINING REGIMEN IN PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN PATIENTS OF BREAST CANCER RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY
description	Objective: To investigate the efficacy of Olanzapine containing regimen as prophylaxis of Chemotherapy Induced Nausea/Vomiting (CINV) in patients with breast cancer, receiving Highly Ematogenic Chemotherapy (HEC). Study Design: Quasi experimental study. Place and Duration of Study: This study was carried out at department of Medical Oncology, CMH Rawalpindi, from Aug 2015 till Feb 2017. Methodology: After meeting the inclusion/exclusion criteria, 44 patient of breast cancer receiving Doxorubicin and Cyclophosphamide chemotherapy, were equally divided in group A and B. Group A received conventional ondansetron IV (8mg), dexamethasone IV (8mg) and Zantac IV (50mg) on day 0 (30 min before chemotherapy) with ondansetron PO (8mg) BD on day 1 and 2, while group B received olanzapine PO (10mg), dexamethasone IV (8mg) and ondansetron IV (8mg) on day 0 with olanzapine PO (10mg) OD on day 1 and 2. Nausea / vomiting scores were calculated in each patient from Day 0 till Day 6. Any episode of rescue medication was also recorded for control of breakthrough nausea/vomiting. The primary efficacy point was to compare complete response between 2 groups, where complete response was defined as Nausea score <2, Vomiting score 0 and no use of rescue medications. Results: Twenty out of 22 patients (90.9%) showed a complete response in group B, whereas only 8 (36.4%) out of 22 (36.4%) patients showed complete response in group A. Conclusion: Olanzapine containing regimen has shown better efficacy than conventional CINV prophylaxis regimen for patients receiving HEC in breast cancer.
format	article
author	Muhammad Umair Iftikhar Hussain Nadeem Piracha Mansoor Zeeshan
author_facet	Muhammad Umair Iftikhar Hussain Nadeem Piracha Mansoor Zeeshan
author_sort	Muhammad Umair
title	EFFICACY OF OLANZAPINE CONTAINING REGIMEN IN PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN PATIENTS OF BREAST CANCER RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY
title_short	EFFICACY OF OLANZAPINE CONTAINING REGIMEN IN PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN PATIENTS OF BREAST CANCER RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY
title_full	EFFICACY OF OLANZAPINE CONTAINING REGIMEN IN PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN PATIENTS OF BREAST CANCER RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY
title_fullStr	EFFICACY OF OLANZAPINE CONTAINING REGIMEN IN PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN PATIENTS OF BREAST CANCER RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY
title_full_unstemmed	EFFICACY OF OLANZAPINE CONTAINING REGIMEN IN PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN PATIENTS OF BREAST CANCER RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY
title_sort	efficacy of olanzapine containing regimen in prevention of chemotherapy induced nausea and vomiting in patients of breast cancer receiving highly emetogenic chemotherapy
publisher	Army Medical College Rawalpindi
publishDate	2019
url	https://doaj.org/article/e0a3d79970564976972276abc7fefc83
work_keys_str_mv	AT muhammadumair efficacyofolanzapinecontainingregimeninpreventionofchemotherapyinducednauseaandvomitinginpatientsofbreastcancerreceivinghighlyemetogenicchemotherapy AT iftikharhussain efficacyofolanzapinecontainingregimeninpreventionofchemotherapyinducednauseaandvomitinginpatientsofbreastcancerreceivinghighlyemetogenicchemotherapy AT nadeempiracha efficacyofolanzapinecontainingregimeninpreventionofchemotherapyinducednauseaandvomitinginpatientsofbreastcancerreceivinghighlyemetogenicchemotherapy AT mansoorzeeshan efficacyofolanzapinecontainingregimeninpreventionofchemotherapyinducednauseaandvomitinginpatientsofbreastcancerreceivinghighlyemetogenicchemotherapy
_version_	1718439638218047488

EFFICACY OF OLANZAPINE CONTAINING REGIMEN IN PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN PATIENTS OF BREAST CANCER RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY

Ejemplares similares